Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × Standard of Care × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 64 Neoplasms 60 Prostatic Neoplasms 45 Colorectal Neoplasms 37 Lung Neoplasms 34 Carcinoma, Non-Small-Cell Lung 24 Hematologic Neoplasms 20 Neoplasm Metastasis 18 Head and Neck Neoplasms 18 Pancreatic Neoplasms 16 Multiple Myeloma 15 Urinary Bladder Neoplasms 14 Ovarian Neoplasms 12 Motor Activity 11 Leukemia, Myeloid, Acute 11 Stomach Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 10 Melanoma 8 Hematopoietic and Lymphatic System Neoplasm 8 Glioblastoma 8 Gastrointestinal Neoplasms 8 Anxiety Disorders 8 Triple Negative Breast Neoplasms 7 Glioma 7 Esophageal Neoplasms 7 Colonic Neoplasms 7 Carcinoma, Renal Cell 7 COVID-19 7 Uterine Cervical Neoplasms 6 Sarcoma 6

Interventions

Cisplatin 11 Everolimus 10 Nivolumab 7 Etoposide 7 Temozolomide 5 Ipilimumab 5 Carboplatin 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 atezolizumab 4 Irinotecan 4 Capecitabine 4 pembrolizumab 3 avelumab 3 Paclitaxel 3 Fluorouracil 3 surufatinib 2 sintilimab 2 gallium Ga 68 dotatate 2 dostarlimab 2 cabozantinib 2 belinostat 2 azaspirane 2 Topotecan 2 Positron Emission Tomography Computed Tomography 2 Magnetic Resonance Imaging 2 Immunoglobulin G 2 IFL protocol 2 Fluorodeoxyglucose F18 2 EC regimen 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07337447 2026-01-13

REWENEC 01

Hospices Civils de Lyon

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡